These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 37214204)
21. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine. Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337 [TBL] [Abstract][Full Text] [Related]
22. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Kok VC Front Oncol; 2020; 10():268. PubMed ID: 32185135 [TBL] [Abstract][Full Text] [Related]
23. Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Shi F; Huang X; Hong Z; Lu N; Huang X; Liu L; Liang T; Bai X Cancer Lett; 2023 May; 562():216167. PubMed ID: 37031916 [TBL] [Abstract][Full Text] [Related]
24. Targeting Strategies for Glucose Metabolic Pathways and T Cells in Colorectal Cancer. Wang G; Wang JJ; Guan R; Sun Y; Shi F; Gao J; Fu XL Curr Cancer Drug Targets; 2019; 19(7):534-550. PubMed ID: 30360743 [TBL] [Abstract][Full Text] [Related]
25. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gaillard SL; Secord AA; Monk B Gynecol Oncol Res Pract; 2016; 3():11. PubMed ID: 27904752 [TBL] [Abstract][Full Text] [Related]
26. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy. Chen S; Duan H; Sun G Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814 [TBL] [Abstract][Full Text] [Related]
27. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395 [TBL] [Abstract][Full Text] [Related]
28. Manipulating T-cell metabolism to enhance immunotherapy in solid tumor. Chen C; Wang Z; Ding Y; Qin Y Front Immunol; 2022; 13():1090429. PubMed ID: 36618408 [TBL] [Abstract][Full Text] [Related]
29. BRAF inhibitors and their immunological effects in malignant melanoma. Adams R; Coumbe JEM; Coumbe BGT; Thomas J; Willsmore Z; Dimitrievska M; Yasuzawa-Parker M; Hoyle M; Ingar S; Geh JLC; MacKenzie Ross AD; Healy C; Papa S; Lacy KE; Karagiannis SN Expert Rev Clin Immunol; 2022 Apr; 18(4):347-362. PubMed ID: 35195495 [TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725 [TBL] [Abstract][Full Text] [Related]
31. New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment. Sung JY; Cheong JH Cells; 2022 Feb; 11(5):. PubMed ID: 35269390 [TBL] [Abstract][Full Text] [Related]
32. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Wang Y; Deng W; Li N; Neri S; Sharma A; Jiang W; Lin SH Front Pharmacol; 2018; 9():185. PubMed ID: 29556198 [TBL] [Abstract][Full Text] [Related]
33. Effect of metabolism on the immune microenvironment of breast cancer. Zhou Y; Wang H; Luo Y; Tuo B; Liu X; Li T Biochim Biophys Acta Rev Cancer; 2023 Mar; 1878(2):188861. PubMed ID: 36813054 [TBL] [Abstract][Full Text] [Related]
34. Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. Bennani-Baiti N; Thanarajasingam G; Ansell S Expert Rev Clin Immunol; 2016 Jun; 12(6):673-9. PubMed ID: 26818843 [TBL] [Abstract][Full Text] [Related]
35. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149 [TBL] [Abstract][Full Text] [Related]
36. Targeting lactate metabolism for cancer immunotherapy - a matter of precision. Heuser C; Renner K; Kreutz M; Gattinoni L Semin Cancer Biol; 2023 Jan; 88():32-45. PubMed ID: 36496155 [TBL] [Abstract][Full Text] [Related]
37. Metabolism of Immune Cells in the Tumor Microenvironment. Jung JG; Le A Adv Exp Med Biol; 2021; 1311():173-185. PubMed ID: 34014543 [TBL] [Abstract][Full Text] [Related]
38. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. Huang L; Xu H; Peng G Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135 [TBL] [Abstract][Full Text] [Related]
40. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]